Stopped: No eligible patients could be found and funding was lost
The AIDI study has to phases. It's purpose is to capture vital signs using a non-invasive, hand-held, home monitoring device (MouthLab Device) from individuals with COVID-19 or who test positive for SARS-CoV-2 (Phase I) and use an algorithm-based approach to identify individuals at risk of clinical decompensation (Phase II). Up to 500 unvaccinated and partially vaccinated subjects will be included (up to 100 in Phase I and up to 400 in Phase II).
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Collect trends in physiological vital signs and symptom burden to identify individuals who are at risk of clinical decompensation
Timeframe: Daily for 60 days
AIDI evaluation
Timeframe: Daily for 60 days